RLAY Stock - Relay Therapeutics, Inc.
Unlock GoAI Insights for RLAY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $10.01M | $25.55M | $1.38M | $3.03M | $82.65M |
| Gross Profit | $10.01M | $25.55M | $1.38M | $3.03M | $79.11M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 95.7% |
| Operating Income | $-372,468,000 | $-373,000,000 | $-299,275,000 | $-364,698,000 | $-55,796,000 |
| Net Income | $-337,708,000 | $-341,973,000 | $-290,509,000 | $-363,872,000 | $-52,412,000 |
| Net Margin | -3374.7% | -1338.7% | -21036.1% | -12012.9% | -63.4% |
| EPS | $-2.36 | $-2.79 | $-2.59 | $-3.82 | $-2.56 |
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 12th 2025 | Wells Fargo | Upgrade | Overweight | $13 |
| September 4th 2025 | Guggenheim | Resumed | Buy | $15 |
| April 17th 2025 | Wells Fargo | Initiation | Equal Weight | $4 |
| September 10th 2024 | Goldman | Resumed | Buy | $20 |
| September 10th 2024 | Oppenheimer | Downgrade | Perform | - |
| September 10th 2024 | Jefferies | Upgrade | Buy | $16← $10.6 |
| May 10th 2024 | Barclays | Upgrade | Overweight | $15 |
| April 20th 2023 | Jefferies | Upgrade | Hold | $12.5 |
| April 19th 2023 | Raymond James | Upgrade | Strong Buy | $29 |
| April 13th 2023 | Raymond James | Initiation | Outperform | $29 |
| February 3rd 2023 | Oppenheimer | Initiation | Outperform | $33 |
| September 30th 2022 | Barclays | Initiation | Equal Weight | $23 |
| September 2nd 2022 | Stifel | Initiation | Buy | $40 |
| June 6th 2022 | Jefferies | Initiation | Underperform | $13 |
Earnings History & Surprises
RLAYEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $-0.38 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.39 | $-0.43 | -10.3% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.49 | $-0.41 | +16.3% | ✓ BEAT |
Q2 2025 | May 5, 2025 | $-0.50 | $-0.46 | +8.0% | ✓ BEAT |
Q1 2025 | Feb 26, 2025 | $-0.57 | $-0.45 | +21.1% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-0.77 | $-0.63 | +18.2% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.73 | $-0.69 | +5.5% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $-0.70 | $-0.62 | +11.4% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $-0.76 | $-0.67 | +11.8% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-0.83 | $-0.54 | +34.9% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.78 | $-0.81 | -3.8% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-0.70 | $-0.78 | -11.4% | ✗ MISS |
Q1 2023 | Feb 23, 2023 | $-0.71 | $-0.56 | +21.1% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.71 | $-0.76 | -7.0% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-0.62 | $-0.71 | -14.5% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-0.63 | $-0.61 | +3.2% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $-0.60 | $0.36 | +160.0% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.65 | $-0.66 | -1.5% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.48 | $-2.10 | -337.5% | ✗ MISS |
Latest News
Wells Fargo Upgrades Relay Therapeutics to Overweight, Raises Price Target to $13
📈 PositiveRelay Therapeutics shares are trading higher after the company announced a subset analysis of interim clinical data for zovegalisib.
📈 PositiveRelay Therapeutics Presents Subset Analysis Of Interim Phase 3 Data For Zovegalisib At SABCS 2025
➖ NeutralWells Fargo Maintains Equal-Weight on Relay Therapeutics, Raises Price Target to $6
➖ NeutralRelay Therapeutics Q3 EPS $(0.43) Misses $(0.42) Estimate
📉 NegativeGuggenheim Assumes Relay Therapeutics at Buy, Announces Price Target of $15
📈 PositiveHC Wainwright & Co. Maintains Buy on Relay Therapeutics, Lowers Price Target to $14
➖ NeutralFrequently Asked Questions about RLAY
What is RLAY's current stock price?
What is the analyst price target for RLAY?
What sector is Relay Therapeutics, Inc. in?
What is RLAY's market cap?
Does RLAY pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to RLAY for comparison